Novo Nordisk has entered a $2.1 billion deal with biotech firm Vivtex to develop next-generation oral biologic medications for obesity and diabetes, the companies announced Wednesday.
Why it matters: Novo is racing to stay ahead in the booming obesity market, where easier-to-take pills could unlock a much larger pool of patients.
